- Home
- BYSI vs BEAT Comparison
BYSI vs BEAT Comparison
Compare BYSI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | BEAT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 22.7M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYSI | BEAT |
|---|---|---|
| Price | $0.62 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 126.8K | ★ 1.2M |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.96 | $1,197.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.36 |
| 52 Week High | $2.44 | $4.00 |
Technical Indicators
Market Signals| Indicator | BYSI | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 46.29 |
| Support Level | $0.60 | $0.38 |
| Resistance Level | $0.85 | $0.52 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 38.23 | 14.26 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.